Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22487953 | 0.83 | — | — | |
| SCHEMBL20830163 | 0.76 | SMN1; SMN2 (0.38) | L3MBTL1ALDH1A1SMN1; SMN2ADORA3 | |
| SCHEMBL22487733 | 0.75 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1SMN1; SMN2PDE1APDE1B | |
| SCHEMBL12205496 | 0.67 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1SMN1; SMN2DGAT2ADORA3 | |
| SCHEMBL22244252 | 0.67 | DGAT2 (0.39) | L3MBTL1ALDH1A1SMN1; SMN2DGAT2ADORA3 | |
| SCHEMBL19663764 | 0.66 | HTT (0.34) | L3MBTL1ALDH1A1SMN1; SMN2DGAT2ADORA3 | |
| SCHEMBL18949030 | 0.64 | DGAT2 (0.38) | L3MBTL1ALDH1A1SMN1; SMN2DGAT2ADORA3 | |
| SCHEMBL22487728 | 0.64 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1SMN1; SMN2DGAT2ADORA3 | |
| SCHEMBL22487898 | 0.63 | ALDH1A1 (0.52) | ALDH1A1ADORA3ADORA2AADORA1 | |
| SCHEMBL18711469 | 0.63 | PNP (0.57) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | L3MBTL1 4627/4885ALDH1A1 2215/4885SMN1; SMN2 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.